InvestorsHub Logo
Followers 483
Posts 61598
Boards Moderated 14
Alias Born 09/20/2001

Re: None

Monday, 03/20/2017 8:44:27 AM

Monday, March 20, 2017 8:44:27 AM

Post# of 799
Ipatasertib is P2, partnered with Genentech. Apparently it was chosen because of Zaida's unusual genetic mutation. Given the pipeline I see no reason why this news should trash the share price, but the Market can make a mountain out of a molehill

http://www.arraybiopharma.com/product-pipeline



In Peace, In War

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ARRY News